Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
94.16B
Market cap94.16B
Price-Earnings ratio
15.62
Price-Earnings ratio15.62
Dividend yield
5.36%
Dividend yield5.36%
Average volume
14.08M
Average volume14.08M
High today
$46.99
High today$46.99
Low today
$45.52
Low today$45.52
Open price
$46.21
Open price$46.21
Volume
14.18M
Volume14.18M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $46.30. The company's market cap stands at 94.16B, with a P/E ratio of 15.62 and a dividend yield of 5.4%.

As of 2025-11-23, Bristol-Myers Squibb(BMY) stock has fluctuated between $45.52 and $46.99. The current price stands at $46.30, placing the stock +1.7% above today's low and -1.5% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 14.18M, compared to an average daily volume of 14.08M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.

BMY News

Simply Wall St 13h
Should Texas Plavix Lawsuit Prompt Fresh Risk Assessment From Bristol-Myers Squibb Investors?

In November 2025, Texas Attorney General Ken Paxton filed a lawsuit against Bristol-Myers Squibb and Sanofi, alleging the companies failed to disclose that thei...

Should Texas Plavix Lawsuit Prompt Fresh Risk Assessment From Bristol-Myers Squibb Investors?
Nasdaq 22h
BMY Quantitative Stock Analysis

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our P/B Growth Invest...

BMY Quantitative Stock Analysis
Simply Wall St 2d
Assessing Bristol-Myers Squibb After a 19% Drop and Recent Drug Approval News

Curious if Bristol-Myers Squibb is finally a bargain, or whether there is still further to fall? Let’s dig into its value to see if now is the time to pay atten...

Assessing Bristol-Myers Squibb After a 19% Drop and Recent Drug Approval News

Analyst ratings

70%

of 30 ratings
Buy
26.7%
Hold
70%
Sell
3.3%

More BMY News

TipRanks 5d
Bristol-Myers Squibb Adjusts Tender Offer Terms

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Simply Wall St 5d
Bristol-Myers Squibb: Assessing Valuation After a 7% Share Price Rebound

Bristol-Myers Squibb (BMY) shares have had a mixed performance over the past month, gaining around 7%. Investors are closely watching revenue trends and profit...

Bristol-Myers Squibb: Assessing Valuation After a 7% Share Price Rebound

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.